

events.

Most recently, Scholzen *et al.*³³ demonstrated that CH was enhanced in neuropeptidase-knock out mice. It is noteworthy that this effect could be abrogated by injections of a neurokinin-1 receptor (NK-1R)-specific antagonist.³³ This result enables us to postulate that enhancement of signals through NK-1R could enhance CH response by blocking degradation of SP.

Concluding Remarks

The deleterious effects of UVR on cutaneous immunity include failed CH induction, promotion of hapten-specific tolerance, and creation of a systemic immune deficiency. Recent studies on the mechanism of action of UVR have revealed that two cell types not originally included in the SALT concept are important: mast cells and cutaneous nerves. It now appears that mast cells serve as a reservoir of immunomodulatory cytokines. Under normal conditions, *i.e.* when SALT functions normally, immunization through the skin avoids release of these cytokines from mast cells and local and systemic CH emerges. At the same time, neuropeptides stored in cutaneous nerves contain both positive and negative regulators of cutaneous immunity. CGRP appears to function as the chemical messenger, released from UVR-exposed nerve endings, that triggers mast cells to release TNF- α , and thereby engenders the altered immunity. SP, by contrast, has the capacity to promote the induction of CH. The precise cellular target of SP in promoting CH induction is not known, but the fact that nerve termini abut directly on the surface of LC suggests that these APC may act on a SP signal. We have no idea how and why SP acts in normal skin to promote and enhance CH induction, especially since both SP and CGRP are simultaneously released from cutaneous nerves. Perhaps haptens cause the selective release of SP, and unsuppressed CH results, whereas UVR causes the release of both CGRP and SP, and only the former survives long enough to trigger mast cell degranulation. Since Paul Langerhans began the inquiry into the cells that bear his name more than a century ago, there is a kind of poetic justice in the recent realization that cutaneous nerves acting directly or indirectly on LC dictate whether antigen applied to or arising within skin will lead to sensitivity or tolerance.

Acknowledgments: The experimental work described in this communication was partly supported by Grant AR44130 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in USA. Hironori Niizeki was partially supported by the Uehara Memorial Foundation. We are grateful to collaborate with Drs. Paul Bergstresser, Stefano Bacci, Ruoping Dai, Iwao Kurimoto, Toshiaki Nakamura, Tadamichi Shimizu, and Takeshi Yoshikawa. We especially thank Ms. C. Roy and J. Slater for their secretarial assistances.

References

1. Streilein JW: Lymphocyte traffic, T-cell malignancies and the skin. *J Invest Dermatol* 1978; 71: 167-171
2. Toews GB, Bergstresser PR, Streilein JW: Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. *J Immunol* 1980; 124: 445-453
3. Langerhans P: Über die Nerven der menschlichen Haut. *Virch Arch Pathol Anat Physiol* 1868; 44: 325-337
4. Silberberg I, Baer RL, Rosenthal SA: The role of Langerhans cells in allergic contact hypersensitivity. A review of findings in man and guinea pigs. *J Invest Dermatol* 1976; 66: 210-217
5. Stingl G, Katz SI, Clement L, Green I, Shevach EM: Immunologic functions of Ia-bearing epidermal Langerhans cells. *J Immunol* 1978; 121: 2005-2013
6. Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. *J Exp Med* 1973; 137: 1142-1162
7. Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD: Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. *Nature* 1993; 363: 159-163
8. Streilein JW, Grammer SF, Yoshikawa T, Demiden A, Vermeer M: Functional dichotomy between Langerhans cells that present antigen to naive and to memory/effector T lymphocytes. *Immunol Rev* 1990; 117: 159-183
9. Kripke ML: Immunological unresponsiveness induced by ultraviolet radiation. *Immunol Rev* 1984; 80: 87-102
10. Streilein JW: Sunlight and skin-associated lymphoid tissues (SALT): if UVB is the trigger, and TNF α is its mediator, what is the message? *J Invest Dermatol* 1993; 100: 47S-52S
11. Everett MA, Yeagers E, Sayre RM, Olson RL: Penetration of epidermis by ultraviolet rays. *Photochem Photobiol* 1966; 5: 533-542
12. Streilein JW, Bergstresser PR: Genetic basis of ultraviolet-B on contact hypersensitivity. *Immunogenetics* 1988; 27: 252-258
13. Yoshikawa T, Streilein JW: Genetic basis of the effects of ultraviolet light B on cutaneous immunity. Evidence that polymorphism at the TNF α and Lps loci governs susceptibility. *Immunogenetics* 1990; 32: 398-405
14. Shimizu T, Streilein JW: Local and systemic consequences of acute, low-dose ultraviolet B radiation are mediated by different immune regulatory mechanisms. *Eur J Immunol* 1994; 24: 1765-1770
15. Shimizu T, Streilein JW: Evidence that ultraviolet B radiation induces tolerance and impairs induction of contact hypersensitivity by different mechanisms. *Immunology* 1994; 82: 140-148
16. Niizeki H, Streilein JW: Hapten-specific tolerance induced by acute, low-dose ultraviolet B radiation of skin is mediated *via* interleukin-10. *J Invest Dermatol* 1997; 109: 25-30
17. Yarosh DB, Alas L, Kibitel JT, Ullrich S: Urocanic acid isomers, immunosuppressive cytokines and the induction of human immunodeficiency virus. *Photodermatol Photoimmunol Photomed* 1992; 9: 127-130
18. Alard P, Niizeki H, Streilein JW: Mast cells are the source of TNF α that impairs contact hypersensitivity induction after UVB radiation. *J Invest Dermatol* 1997; 108: 592
19. Niizeki H, Alard P, Streilein JW: Calcitonin gene-related peptide (CGRP) mediates the deleterious effects of acute, low dose ultraviolet B radiation (UVR). *J Invest Dermatol* 1997; 108: 559
20. Alard P, Niizeki H, Streilein JW: Mast cells are required for systemic tolerance after UVB radiation. *J Invest Dermatol* 1997; 109: 254